Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2002-07-12
2008-11-11
Nickol, Gary B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085500, C424S130100, C424S133100, C424S143100, C530S333000, C530S351000, C530S386000, C514S002600, C435S007100
Reexamination Certificate
active
07449176
ABSTRACT:
The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
REFERENCES:
patent: 4676982 (1987-06-01), Hassig
patent: 4727138 (1988-02-01), Goeddel et al.
patent: 4762791 (1988-08-01), Goeddel et al.
patent: 4897264 (1990-01-01), Novick et al.
patent: 4925793 (1990-05-01), Goeddel et al.
patent: 4929554 (1990-05-01), Goeddel et al.
patent: 5451658 (1995-09-01), Seelig
patent: 6329511 (2001-12-01), Vasquez et al.
patent: 2005/0019323 (2005-01-01), Ehrhardt et al.
patent: 240975 (1987-10-01), None
patent: 0 269 408 (1988-06-01), None
patent: 0 269 408 (1988-06-01), None
patent: 369413 (1990-05-01), None
patent: 393502 (1990-10-01), None
patent: 416652 (1991-03-01), None
patent: 0 614 981 (1994-09-01), None
patent: WO 90/14359 (1990-11-01), None
patent: WO 91/16431 (1991-10-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 03/097082 (2003-11-01), None
Aguet et al., “Molecular Cloning and Expression of the Human Interferon-γ Receptor”,Cell, 55:273-280 (1988).
Billiau, A., “Gamma-interferon: the match that lights the fire?”,Immunology Today, 9:37-40 (1988).
Brandtzaeg, P. et al., “Immunopathology of Crohn's Disease”,Ann. Gastroenterol. Hepatol., 21(4), pp. 201-220 (1985).
Brandtzaeg, P. et al., “Mucosal Immune System in Inflammatory Bowel Disease”,Immunology and Medicine Series, 19:19-39 (1992).
Byrn et al., “Biological properties of a CD4 immunoadhesin”,Nature, 344:667-670 (1990).
Coffman and Carty, A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-γ,J. Immunol., 135:949-954 (1986).
Cominelli, F. et al., “Interleukin 1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis”,J. Clin. Invest., 86:972-980 (1990).
Dembic et al., “Prevention of streptozotocin induced diabetes in mice with the IFN-γ receptor immunoadhesins”, abstract No. P7-3, 1992 ISIR Meeting Annual Mtg on the Interferon System, Toronto, Ontario, Canada, Sep. 28-Oct. 2, 1992,J. of Interferon Research, Mary Ann Liebert, Inc., Pubs.
Didlake et al., “Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograf survival in the rat”,Transplantation, 45:222-223 (1988).
Döbeli, H. et al., Role of the carboxy-terminal sequence on the biological activity of human Interferon (IFN-γ);J. Biotech., 7:199-216 (1988).
Ealick, S.E. et al., “Three-dimensional structure of recombinant human interferon-γ”,Science, 252:698-702 (1991).
Fais et al., “Spontaneous Release of Interferon γ by Intestinal Lamina Propria Lymphocytes in Crohn's Disease. Kinetics of In Vitro Response to Interferon γ Inducers,”Gut32:403-407 (1991).
Fais, S. et al., “HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers”,Clin. Ex. Immunol., 68:605-612 (1987).
Favre, C. et al., “Epitope mapping of recombinant human gamma interferon using monoclonal antibodies”,Mol. Immunol., 26(1):17-25 (1989).
Haak-Frendscho et al., “Inhibition of interferon-γ by an interferon-γ receptor immunoadhesin”,Immunology, 79:594-599 (1993).
Harris et al., “Therapeutic Antibodies—the Coming of Age”,Tibtech, 11:42-44 (1993).
Heremans et al., “Interferon γ, a mediator of lethal lipopolysaccharide-induced shwartzman-like shock reactions in mice”,J. Exp. Med., 171:1853-1869 (1990).
Hochkeppel and de Ley, “Monoclonal antibody against human IFN-γ”,Nature, 296(5854):258-259 (1982).
Hodges et al., “Phase 1 Study of Recombinant Human CD4-Immunoglobulin G Therapy of Patients with AIDS and AIDS-Related Complex”,Antimicrobial Agents&Chemotherapy, 35(22):2580-2586 (1991).
Hogrefe, H. H. et al., “Amino terminus is essential to the structural integrity of recombinant human interferon”,J. Biol. Chem., 264(21):12179-12186 (1989).
Jacob et al., “In vivo treatment of (NZB×NZW)F1lupus-like nephritis with monoclonal antibody to γ interferon”,J. Exp. Med., 166:798-803 (1987).
Jarpe, M.A. et al., “Topology of receptor binding domains of mouse IFN-γ”,J. Immunol., 145:3304-3309 (1990).
Khurana Hershey and Schreiber, “Biosynthetic Analysis of the Human Interferon-γ Receptor”,J. Biol. Chem., 264(20):11981-11988 (1989).
Kuerschner, “Interferon- γ Receptor/Immunoglobulin Hybrid Molecules as Inhibitors of IFN γ Function”,J. Interferon Res., 11(Suppl. 1):S62 (ISR Meeting, Nov. 3-8, 1991).
Kuerschner, C. et al., “Construction, purification, and characterization of new interferon γ (IFNγ) inhibitor proteins. Three IFNγ receptor-immunoglobulin hybrid molecules”, CA 116:253810w (1992).
Kuhn, R. et al., “IL-4 and IL-10 deficient mice”, 8thInt'l Congress of Immunology, abstract No. 18, Budapest, Hungary, Aug. 22-28, 1992.
Kürschner, C. et al., “Construction, Purification, and Characterization of New Interferon γ (IFN-γ) Inhibitor Proteins”,J. Biol. Chem., 267(13):9354-9360 (1992).
Kürschner, C. et al., “IFN-γ, Receptor-Ig Fusion Proteins: Half-Life, Immunogenicity, and In Vivo Activity”,J. Immunol., 149(12):4096-4100 (1992).
Kusugami, K. et al., “Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis and controls”,Gastroenterology, 97:1-9 (1989).
Leinikki, P.O. et al., “Reduced receptor binding by a human interferon-γ fragment lacking 11 carboxyl-terminal amino acids”,J. Immun., 139(10):3360-3366 (1987).
Ligumsky, M. et al., “Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease”,Gut, 31:686-689 (1990).
Lionetti et al, “Activation of mucosal Vβ3+T cells and tissue damage in human small intestine by the bacteria superantigen,Staphyloccus aureusenterotoxin B”,Eur. J. Immunol., 23:664-668 (93).
Lord, S.C. et al., “Functional domains of human interferon gamma probed with antipeptide antibodies”,Mol. Immun., 26(7):637-640 (1989).
Lunn, C.A. et al., “An active covalently linked dimer of human interferon-γ”,J. Biol. Chem., 267:17920-17924 (1992).
MacDermott, R.P. et al., “Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease”,Gastroenterology, 96:764-768 (1989).
MacDonald & Spencer, “Cell-mediated immune injury in the intestine”,Gastroenterology Clinics of North America, 21(2):367-386 (1992).
MacDonald, T.T. et al., “Tumour necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine”,Clin. Exp. Immunol., 81:301-305 (1990).
Magazine and Johnson, “Characterization of a Synthetic Peptide Corresponding to a Receptor Binding Domain of Mouse Interferon”,Biochemistry, 30:5784-5789 (1991).
Mahida, Y.R. et al., “Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease”,Gut, 30:835-838 (1989).
Murch et al., “Disruption of sulphated glycosaminoglycans in intestinal inflammation”,The Lancet, 341:711-714 (1993).
Ozmen et al., “Effect of soluble MoIFNγ-R treatment on the development of spontaneous autoimmune disease in NZB/W F1 mice”, abstract No. 5.19, 1992 ISIR Meeting Annual Mtg. on the Interferon System, Toronto, Ontario, Canada, Sep. 28-Oct. 2, 1992,J. of Interferon Researc
Ashkenazi Avi J.
Ward Rebecca H. R.
Basi Nirmal S
Genentech Inc.
Morrison & Foerster / LLP
Nickol Gary B.
LandOfFree
Treatment of inflammatory bowel disease with IFN-γ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammatory bowel disease with IFN-γ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory bowel disease with IFN-γ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028322